[1] Nasiria, F., Mokhtaria, J., Taherib, S., & Mirjafaria, Z. (2025). Synthesis of Montelukast using dichloroimidazolidinedione (DCID). Applied Chemistry Today, 20(76), 65-74. (in Persian)
[2] Alizadeh, N., Kiyani, H., & Albadi, J. (2023). Green and three-component synthesis of isoxazolones using natural sunlight and investigating their antibacterial activity. Applied Chemistry Today, 18(67), 125-148. (in Persian)
[3] Shiri, M. , fazelzadeh, S. , Faghihi, Z. and Notash, B. (2018). Using highly substituted isocyanides in the synthesis ofiminothiophenes fused to quinolines. Applied Chemistry Today, 13(48), 231-240. (in Persian)
[4] Zali-Boeini, H. , Amiri Rudbari, H. and Hajibabaei, K. (2019). Direct and efficient conversion of thioamides to benzazole derivatives using N,N'-dibromophenytoin. Applied Chemistry Today, 14(50), 105-112. (in Persian)
[5] Darzi daroonkala, M. and Kiyani, H. (2019). Synthesis of 1,3-diazabicyclo[3.1.0]hex-3-en-2-yl-4H-chromen-4-ones as photochromic compounds. Applied Chemistry Today, 14(52), 307-320. (in Persian)
[6] Pragi, A., Varun, A., Lamba, H. S., & Wadha, D. (2012). Importance of heterocyclic chemistry. International Journal of Pharmaceutical Science and Research, 15(4), 421–429.
[7] Xiong, S. Y., Wang, Y., Shen, L. Y., Zhang, Q. L., Redshaw, C., & Chen, M. H. (2025). Substituent effects on axial chiral compound enantiomers: synthesis and crystal structures of axially chiral 1, 3, 4-oxadiazole thioethers (Sulfones) based on 2, 2′-bipyridine. Journal of Molecular Structure, 1323, 140632.
[8] Ahmed, K., Choudhary, M. I., & Saleem, R. S. Z. (2023). Heterocyclic pyrimidine derivatives as promising antibacterial agents. European Journal of Medicinal Chemistry, 259, 115701.
[9] dos Santos, G. C., Martins, L. M., Bregadiolli, B. A., Moreno, V. F., da Silva‐Filho, L. C., & da Silva, B. H. S. T. (2021). Heterocyclic compounds as antiviral drugs: Synthesis, structure–activity relationship and traditional applications. Journal of Heterocyclic Chemistry, 58(12), 2226-2260.
[10] Farzamnezhad, I., Sheikhi-Mohammareh, S., Beyzaei, H., Yarmohammadi, E., & Shiri, A. (2024). Synthesis of novel DPPH-free radical scavenger Se-containing fused chalcogenophenes: 2-Alkyl-7-cyano-4-imino-3-phenyl-6-(pyrrolidin-1-yl)-3, 4-dihydroselenopheno [3, 2-d] pyrimidines. Polycyclic Aromatic Compounds, 44(2), 807–817.
[11] Lang, D. K., Kaur, R., Arora, R., Saini, B., & Arora, S. (2020). Nitrogen-containing heterocycles as anticancer agents: An overview. Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Anti-Cancer Agents), 20(18), 2150–2168.
[12] Laird, T. (2013). Pyridines: From lab to production. American Chemical Society.
[13] Nivedya, T., Ramasamy, S. K., Jose, J., & Kumar, S. K. A. (2025). Effect of 6, 6-substitution on 2, 2’-bipyridine and probing biomolecular interaction through experimental and computational studies towards anticancer potency. Journal of Fluorescence. Advance online publication, 1–15.
[14] Hossaini, Z., Shafaei, F., Sheikholeslami-Farahani, F., & Ghasemi, N. (2020). Fe3O4-magnetic nanoparticles from essential oil of orange peel catalyzed green synthesis of pyridine derivatives: Study of antioxidant activity of some synthesised compounds Applied Chemistry Today, 15(54), 243–256.
[15] Ghasemzadeh, M. A., Mirhosseini-Eshkevari, B., & Esnaashari, M. (2020). Synthesis, characterization and investigation of catalytic properties of NiCo2O4@Ni(BDC) metal-organic framework in the preparation of c (in persian), hromeno[2,3-b]pyridine derivatives Applied Chemistry Today, 15(56), 101–116. (in persian)
[16] Gopathi, R., Kumar, M. P., Kumar, G. J., NP, S., Kodiripaka, B. G., Naidu, V. G. M., & Babu, B. N. (2025). Exploration of the cytotoxic and microtubule disruption potential of novel imidazo [1, 5-a] pyridine-based chalcones. RSC Medicinal Chemistry, 16(3), 1188–1198.
[17] Suntornlekha, N., Tajarernmuang, P., Srisurapanont, M., & Chittawatanarat, K. (2025). Benefit of inodilators in septic shock patients: A systematic review and network meta-analysis: Inodilators in septic shock: Network meta-analysis. Clinical Critical Care, 33, Article e250007.
[18] Kumar, C. N. S. S. P., & Jayathirtha, V. R. (2025). Bioactive molecules via Morita–Baylis–Hillman chemistry. Synlett. Advance online publication.
[19] Pradhan, S., Janhavi, B., & Das, T. M. (2025). Recent advances in the synthesis and applications of partially protected N-glycosylamines. Current Organic Chemistry, 29(5), 402–420.
[20] Magalhães, D. W. A., Sidrônio, M. G. S., Nogueira, N. N., Carvalho, D. C. M., de Freitas, M. E. G., Oliveira, E. C., ... & Rodrigues-Mascarenhas, S. (2025). Evaluation of the anti-mycobacterial and anti-inflammatory activities of the new cardiotonic steroid γ-benzylidene digoxin-15 in macrophage models of infection. Microorganisms, 13(2), 269.
[21] Kwon, Y., & Kim, W. (2022). Protecting group‐controlled regioselective synthesis for unsymmetrical 3, 5‐disubstituted pyridones. Advanced Synthesis & Catalysis, 364(8), 1440–1449.
[22] Shulgau, Z., Palamarchuk, I., Dezhko, E., Sergazy, S., Urazbayeva, A., Safarova, Y., ... & Kulakov, I. (2025). Synthesis, Structure and Cytoprotective Activity of New Derivatives of 4-Aryl-3-Aminopyridin-2 (1 H)-One. Molecules, 30(16), 3331.
[23] Müller, C. E., Nicke, A., Lohr, C., Freichel, M., & Guse, A. H. (2025). Call for papers–Purinergic signaling: Medicinal chemistry, biology, pharmacology, and translation into diagnostic and therapeutic drugs. ACS Pharmacology & Translational Science, 8(3), 617–620.
[24] Zolfigol, M. A., Moqsoodi, M., Zare, A., Moosavi Zare, A. R., & Ragheb, F. (2017). Isatin-N-sulfonic acid as a new, efficient and reusable catalyst for the synthesis of 2-amido-alkyl-phenols under solvent-free conditions Applied Chemistry Today, 12(42), 197–208. (in persian)
[25] Tarahhomi, A. , Pourayoubi, M. , Golen, J. A. and Rheingold, A. L. (2017). Synthesis, characterization and structural study of new phosphoric triamides. Applied Chemistry Today, 12(42), 243-252.
[26] Gholamrezaeia, Z. and Tarahhomi, A. (2024). Synthesis and Characterization of New Phosphoramide Compounds and Study of Their Inhibitory Effects Against Corona and Monkeypox Viruses by using Molecular Docking Method. Applied Chemistry Today, 20(74), 25-40. (in Persian)
[27] Ward, A., Brogden, R. N., Heel, R. C., Speight, T. M., & Avery, G. S. (1983). Amrinone: A preliminary review of its pharmacological properties and therapeutic use. Drugs, 26(6), 468–502.
[28] Mancini, D., LeJemtel, T., & Sonnenblick, E. (1985). Intravenous use of amrinone for the treatment of the failing heart. The American Journal of Cardiology, 56(3), 8B–15B.
[29] Bristow, M. R. (2011). Treatment of chronic heart failure with β-adrenergic receptor antagonists: A convergence of receptor pharmacology and clinical cardiology. Circulation Research, 109(10), 1176–1194.
[30] McNamara, P. J., Chock, V. Y., Rahde-Bischoff, A., Gabrio, J., Johnson, K., Harmon, H., ... & Bell, E. (2025). Evaluating the efficacy and safety of milrinone for prevention of post-patent ductus arteriosus closure syndrome (the MIDAS trial) in extremely preterm infants: a multicentre, double-masked, randomised, placebo-controlled trial. BMJ open, 15(8), e105018.
[31] Kuzmiszyn, A. K., Selli, A. L., Smaglyukova, N., Kondratiev, T., Fuskevåg, O. M., Lyså, R. A., ... & Dietrichs, E. S. (2022). Treatment of cardiovascular dysfunction with PDE3-inhibitors in moderate and severe hypothermia—effects on cellular elimination of cyclic adenosine monophosphate and cyclic guanosine monophosphate. Frontiers in physiology, 13, 923091.
[32] Trawally, M. (2023). Beyond the heart—Exploring the therapeutic potential of PDE3 inhibitors. Journal of Research in Pharmacy, 27(6), 2218–2241.
[33] Silverman, B. D., Merrill, A. J., & Gerber, L. (1985). Clinical effects and side effects of amrinone: A study of 24 patients with chronic congestive heart failure. Archives of Internal Medicine, 145(5), 825–829.
[34] Gupta, A., & Preuss, C. V. (2023). Inamrinone. In StatPearls. StatPearls Publishing.
[35] Wilmshurst, P. T., & Webb-Peploe, M. M. (1983). Side effects of amrinone therapy. Heart, 49(5), 447–451.
[36] Alousi, A. A., & Dobreck, H. P. (1983). Cardiac stimulants. In New drugs annual: Cardiovascular drugs (Vol. 1, pp. 259–276). Raven Press.
[37] Vardanyan, R., & Hruby, V. (2006). Synthesis of essential drugs. Elsevier.
[38] Lesher, G. Y., & Opalka Jr, C. J. (1978). U.S. Patent No. 4,072,746. Washington, DC: U.S. Patent and Trademark Office.
